PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 25, 2026The American Surgeon0 citations

Comorbidity Burden as a Determinant of Treatment Pathway After Percutaneous Cholecystostomy Tube Placement for Acute Cholecystitis: Experience From an Appalachian Tertiary Referral Center

View Full Paper
HJHunter JohnsonTDTim DonovanGSGabe Smith

Key Points

  • To explore how comorbidity burden affects treatment pathways after percutaneous cholecystostomy placement in acute cholecystitis patients.
  • Retrospective observational case series examining 139 patients treated with percutaneous cholecystostomy for acute cholecystitis.
  • Data collected on comorbidities and treatment outcomes from October 2020 to March 2025.
  • Charlson Comorbidity Index scores were assessed to evaluate risk factors for treatment progression.
  • 31.7% (n = 44) of patients progressed to cholecystectomy, resulting in 78.7% lower 6-month mortality compared to non-operative management (P < .001).
  • Patients progressing to cholecystectomy had significantly lower Charlson Comorbidity Index scores (3.89 vs. 5.57; P = .05).
  • Lower likelihood of active cancer (P = .002), COPD (P = .001), and CHF (P = 0.032) was observed in those who underwent cholecystectomy.

Abstract

Comorbidity burden in patients with acute cholecystitis (AC) managed by percutaneous cholecystostomy tube (PCT) placement may determine whether patients progress to cholecystectomy (CCY) or require ongoing non-operative management. This retrospective observational case series examined 139 patients admitted with PCT placement for AC at a rural Appalachian tertiary referral center between October 2020 and March 2025. The most prevalent comorbidities among these patients were hypertension (79.9%), smoking (61.2%), and hyperlipidemia (47.5%). Of the 139 patients, 31.7% (n = 44) underwent subsequent CCY and had 78.7% lower 6-month mortality compared to those managed non-operatively ( P < .001). Patients progressing to CCY had significantly lower Charlson Comorbidity Index (CCI) scores (3.89 vs. 5.57, P = .05) and were significantly less likely to have active cancer ( P = .002), COPD ( P = .001), or CHF ( P = 0.032). In resource-constrained environments where advanced endoscopic alternatives are unavailable, these comorbidity profiles can guide preoperative risk stratification and inform individualized counseling regarding anticipated treatment pathways after PCT.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Johnson et al. (2026) studied this question.

synapsesocial.com/papers/6a13e81d0e02ee3982d32d82https://doi.org/10.1177/00031348261455083
Ask AI
Helpful
Bookmark
Share
View Full Paper